These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 3580507)

  • 1. Relationship between proliferative activity of bone marrow micrometastasis and plasmatic level of a new cancer marker: lipid associated sialic acid (LASA) in human breast cancer.
    Ginsbourg M; Musset M; Misset JL; Mathé G
    Biomed Pharmacother; 1986; 40(10):388-91. PubMed ID: 3580507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum lipid-bound sialic acid as a tumoral marker in minimal residual tumors.
    Musset M; Mathé G; Reizenstein P
    Bull Soc Sci Med Grand Duche Luxemb; 1989; 126(1):17-20. PubMed ID: 2663215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous detection in the bone marrow of mammary cancer metastatic cells and of their labelling index as respective markers of the residual minimum submacroscopic disease and its proliferative condition (preliminary results).
    Ginsbourg M; Musset M; Misset JL; Genty O; Mathé G
    Biomed Pharmacother; 1986; 40(10):386-8. PubMed ID: 3555638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer.
    Diel IJ; Cote RJ
    Cancer Treat Rev; 2000 Feb; 26(1):53-65. PubMed ID: 10660491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer and family history: levels of lipid-associated sialic acid in plasma and absent family history of breast cancer in women who have breast tumors.
    Brower ST; Tartter P; Weiss S; Luderer AA; Lehrer S
    Mt Sinai J Med; 1995 Nov; 62(6):419-21. PubMed ID: 8692154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of mammary metastatic cells in the bone marrow as a marker of a minimal residual disease and of their proliferative index as a factor of prognosis--an immunocytologic study with monoclonal antibodies.
    Ginsbourg M; Musset M; Misset JL; Genty O; Mathé G
    Bull Soc Sci Med Grand Duche Luxemb; 1989; 126(1):51-4. PubMed ID: 2743531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of mammary metastatic cells in the bone marrow as a marker of a minimal residual disease and of their proliferative index as a factor of prognosis--an immunocytologic study with monoclonal antibodies.
    Ginsbourg M; Musset M; Misset JL; Genty O; Mathé G
    Suppl J Med Oncol Tumor Pharmacother; 1988; 1():51-4. PubMed ID: 3074227
    [No Abstract]   [Full Text] [Related]  

  • 8. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity.
    Müller V; Stahmann N; Riethdorf S; Rau T; Zabel T; Goetz A; Jänicke F; Pantel K
    Clin Cancer Res; 2005 May; 11(10):3678-85. PubMed ID: 15897564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disseminated tumor cells in pancreatic cancer patients detected by immunocytology: a new prognostic factor.
    Vogel I; Krüger U; Marxsen J; Soeth E; Kalthoff H; Henne-Bruns D; Kremer B; Juhl H
    Clin Cancer Res; 1999 Mar; 5(3):593-9. PubMed ID: 10100711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer.
    Giai M; Natoli C; Sismondi P; Biglia N; Lesti G; Mulieri M; Iacobelli S
    Anticancer Res; 1990; 10(1):119-21. PubMed ID: 2334117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection and management of bone marrow micrometastases in breast cancer.
    Osborne MP; Rosen PP
    Oncology (Williston Park); 1994 Aug; 8(8):25-31; discussion 35-6, 39-42. PubMed ID: 7947000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.
    Bidard FC; Vincent-Salomon A; Gomme S; Nos C; de Rycke Y; Thiery JP; Sigal-Zafrani B; Mignot L; Sastre-Garau X; Pierga JY;
    Clin Cancer Res; 2008 Jun; 14(11):3306-11. PubMed ID: 18519757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer.
    Benoy IH; Salgado R; Elst H; Van Dam P; Weyler J; Van Marck E; Scharpé S; Vermeulen PB; Dirix LY
    Breast Cancer Res; 2005; 7(2):R210-9. PubMed ID: 15743502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of immunocytochemical detection of breast cancer cells in human bone marrow.
    Osborne MP; Wong GY; Asina S; Old LJ; Cote RJ; Rosen PP
    Cancer Res; 1991 May; 51(10):2706-9. PubMed ID: 2021949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients.
    Masuda TA; Kataoka A; Ohno S; Murakami S; Mimori K; Utsunomiya T; Inoue H; Tsutsui S; Kinoshita J; Masuda N; Moriyama N; Mori M
    Int J Oncol; 2005 Mar; 26(3):721-30. PubMed ID: 15703829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of disseminated carcinoma cells in bone marrow and peripheral blood in primary breast cancer with RT/PCR of parathyroid hormone-related protein (PTHrP)].
    Liersch T; Gatzemeier W; Scharnberg P; Jürgens B; Wörmann B; Becker H; Rauschecker HF; Hiddemann W; Wulf GG
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):277-80. PubMed ID: 14518259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application?
    Lang JE; Hall CS; Singh B; Lucci A
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1463-72. PubMed ID: 17944570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of a panel of mRNA markers in the detection of disseminated tumor cells in patients with operable breast cancer.
    Varangot M; Barrios E; Sóñora C; Aizen B; Pressa C; Estrugo R; Lavigna R; Musé I; Osinaga E; Berois N
    Oncol Rep; 2005 Aug; 14(2):537-45. PubMed ID: 16012742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support.
    Vredenburgh JJ; Silva O; Broadwater G; Berry D; DeSombre K; Tyer C; Petros WP; Peters WP; Bast RC
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):91-7. PubMed ID: 9267669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular detection of disseminated breast cancer cells in the bone marrow of early breast cancer patients using quantitative RT PCR for CEA.
    Janku F; Srovnal J; Korinkova G; Novotny J; Petruzelka L; Power D; Matous B; Hajduch M
    Neoplasma; 2008; 55(4):317-22. PubMed ID: 18505343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.